Recursion Pharmaceuticals CEO Christopher Gibson acquired 5,000 shares of the company's common stock on 08/28/2024. The transaction was executed at a price of $2.48 per share, reflecting a total investment of $12,400. Following this purchase, Gibson's direct holdings in Recursion Pharmaceuticals increased to 752,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security, indicating a potential increase in the executive's confidence in the company's future prospects.

Recursion Pharmaceuticals CEO Christopher Gibson acquired 5,000 shares of the company's common stock on 08/28/2024. The transaction was executed at a price of $2.48 per share, reflecting a total investment of $12,400. Following this purchase, Gibson's direct holdings in Recursion Pharmaceuticals increased to 752,656 shares. The transaction, which is currently in progress, was reported as an exercise or conversion of derivative security, indicating a potential increase in the executive's confidence in the company's future prospects.